华蟾素胶囊联合化疗治疗晚期卵巢癌临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R737.31

基金项目:


Clinical Study on Huachansu Capsules Combined with Chemotherapy for Advanced Ovarian Cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察华蟾素胶囊联合多西他赛注射液、卡铂注射液治疗晚期卵巢癌的临床疗效及对细胞免 疫功能的影响。方法:按随机数字表法将106 例晚期卵巢癌分为对照组与治疗组各53 例。对照组采取多西他 赛注射液、卡铂注射液治疗,治疗组在对照组基础上联合华蟾素胶囊治疗。比较2 组治疗前后细胞免疫指 标(T 淋巴细胞亚群CD4+、CD8+、CD4+/CD8+)、卵巢癌特异性量表第4 版(FACT-OV4) 评分变化,分析临床 疗效和不良反应发生率。结果:治疗组总有效率为98.11%,对照组为84.91%,2 组比较,差异有统计学意 义(P<0.05)。治疗后,2 组CD4+、CD4+/CD8+水平均较治疗前升高(P<0.05),CD8+水平较治疗前降低(P< 0.05);且治疗组CD4+、CD4+/CD8+水平高于对照组(P<0.05),CD8+水平低于对照组(P<0.05)。治疗后, 2 组FACT-OV4 量表生理状况、情感状况和附加关注评分均较治疗前降低(P<0.05),功能状况、社会状况评 分均较治疗前升高(P<0.05);且治疗组生理状况、情感状况和附加关注评分均低于对照组(P<0.05),功能 状况、社会状况评分均高于对照组(P<0.05)。治疗期间,治疗组不良反应发生率为3.77%,对照组为 18.87%,2 组比较,差异有统计学意义(P<0.05)。结论:华蟾素胶囊联合多西他赛注射液、卡铂注射液治疗 晚期卵巢癌疗效优于单纯西药化疗,能有效改善患者细胞免疫功能,提高生活质量,且不良反应较少。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Huachansu Capsules combined with Docetaxel Injection and Carboplatin Injection on advanced ovarian cancer and its effect on cellular immune function. Methods:A total of 106 cases of patients with advanced ovarian cancer were divided into the control group and the treatment group according to the random number table method,with 53 cases in each group. The control group was treated with Docetaxel Injection and Carboplatin Injection,and the treatment group was additionally treated with Huachansu Capsules based on the treatment of the control group. The changes in cellular immune indexes [T lymphocyte subsets (CD4+,CD8+,CD4+/CD8+ ) and Functional Assessment of Cancer Therapy-Ovary Cancer (FACT-OV4) scores before and after treatment were compared between the two groups;clinical effects and incidence of adverse reactions were analyzed. Results:The total effective rate was 98.11% in the treatment group and 84.91% in the control group,the difference being significant (P<0.05). After treatment, the levels of CD4 + and CD4 +/CD8 + in the two groups were increased when compared with those before treatment (P<0.05),and CD8 + levels were decreased when compared with those before treatment (P<0.05);the levels of CD4 + and CD4 +/CD8 + in the treatment group were higher than those in the control group (P<0.05),CD8 + level was lower than that in the control group (P<0.05). After treatment,the physiological status,emotional status and additional attention scores of FACT- OV4 scale in the two groups were decreased when compared with those before treatment (P<0.05),and the scores of functional status and social status were increased when compared with those before treatment (P<0.05); the scores of physiological status, emotional status and additional attention in the treatment group were lower than those in the control group (P<0.05),and the scores of functional status and social status were higher than those in the control group (P<0.05). During the treatment period,the incidence of adverse reactions was 3.77% in the treatment group and 18.87% in the control group,the difference being significant (P<0.05). Conclusion:Huachansu Capsules combined with Docetaxel Injection and Carboplatin Injection has a better curative effect than simple chemotherapy with western medicine in the treatment of advanced ovarian cancer,and it can effectively improve the cellular immune function and quality of life of patients,with fewer adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

范道艳,贾景香,库玉花,王静,段予,李芳,于瑞蒙.华蟾素胶囊联合化疗治疗晚期卵巢癌临床研究[J].新中医,2024,56(2):134-138

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-01-25
  • 出版日期:
文章二维码